

concentration-percent cell-survival curves and were defined as the concentrations of phenoxazines required for 50% reduction in colonies compared to controls (Table II).

Effect of N-Substituted Phenoxazines on in Vitro Cytotoxicity of VLB and VCR. Cells were treated with graded concentrations of VCR and VLB in the absence or presence of nontoxic concentrations (Table III) of compounds 1, 3, 4, 11, or 18. The plates were then transferred to a CO₂ incubator and, after further incubation for 7 days at 37 °C, colonies were enumerated as described.

Acknowledgment. We wish to thank Dr. M. Gottesman for making available the KB cell lines. This work was

supported in part by award CH-423 from the American Cancer Society, by United States Public Health Service grants CA-23099, CA-40570 and CA-21765 for Cancer Center Support (CORE) from the National Cancer Institute, and by the American Lebanese Syrian Associated Charities (ALSAC). The authors sincerely thank Dr. Winston D. Lloyd, Department of Chemistry, University of Texas at El Paso, for his cooperation to record the NMR spectra. The authors also thank Drs. Henry K. Myszkowski and Xiao-Xin Zhou for their cooperation. Excellent word processing assistance by Vicki Gray is gratefully appreciated.

Synthesis and Biological Activity of Ketomethylene Pseudopeptide Analogues as Thrombin Inhibitors¹

Leifeng Cheng,*† Christopher A. Goodwin, Michael F. Schully, Vijay V. Kakkar, and Göran Claesson*

Thrombosis Research Institute, Manresa Road, London SW3 6LR, U.K. Received February 10, 1992

Ketomethylene pseudopeptide analogues Aa-Pro-Argψ(COCH₂)Gly-pip, 1, where Aa are D- or L-amino acids (Dpa, β,β-diphenylalanine; αNal, α-naphthylalanine; βNal, β-naphthylalanine; Fgl, fluorenylglycine) with highly lipophilic side chains and ψ(COCH₂) is a ketomethylene pseudopeptide bond, have been synthesized through a modified Dakin-West reaction under very mild conditions with a high yield using tripeptide 4 with a labile functional group directly on the side chain. Their enzymatic assay of thrombin inhibition has been carried out. The structure-activity relationship study indicated that a lipophilic side chain on the amino acid in the P₃ position is very important for binding to the apolar site of thrombin. Compound 1a with D-pa at the P₃ position has a K_i of 0.2 μM and it doubles thrombin clotting time at only 3 times higher concentration. These values are about 7 times better than those of the corresponding D-Phe analogues. Furthermore, 1a shows poor inhibitory activity against plasmin, factor Xa, urokinase, and kallikrein. Preliminary in vivo testing (3–4 kg rabbit as the animal model) shows no observable side effect (change of blood pressure and accumulation of blood platelet in lungs) at a dose of 1 mg/kg.

Interest in the design of synthetic inhibitors of serine proteases and especially of thrombin has grown enormously during the last few years. One type of such inhibitors is the ketomethylene pseudopeptide analogues, in which the -NH- group of the scissile P₁-P₁' bond, corresponding to the natural substrate, has been replaced by a methylene group. This type of peptide inhibitor has several advantages. Firstly, the ketomethylene bond is resistant to enzymatic degradation. Secondly, the keto group can possibly form a tetrahedral semi-ketal with the active site serine hydroxyl. Thirdly, the amino acid sequence on the carbonyl side of the ketomethylene bond can add binding affinity to the inhibitor.

The peptide sequence D-Phe-Pro-Arg, imitating the natural substrate of thrombin, has been widely used as a basis for inhibitors and substrates of thrombin.²⁻⁶ The ketomethylene peptide analogue D-Phe-Pro-Argψ(COCH₂)Gly-pip, synthesized by Szelke and Jones,⁶ showed good inhibitory activity toward thrombin.⁷

In the course of our studies on thrombin peptide inhibitors, it is found that a lipophilic side chain on the amino acid in the P₃ position is very important for binding to the apolar site of thrombin. We here report the synthesis and antithrombin effect of inhibitors with the structure shown in formula 1 (Scheme I), where D-Phe in the sequence D-Phe-Pro-Arg has been replaced by some unnatural, aromatic amino acids.

To introduce the ketomethylene moiety into the compound, Szelke and Jones⁶ used a Dakin-West reaction⁸ with N^α-formyl-protected amino acid as the starting material. This method gave us a very poor yield (1%). The benzene ring of an N^α-benzoyl amino acid activates the

oxazolone intermediate. We obtained a good yield (58%) by this method, but the very harsh conditions (HCl/AcOH/H₂O, 120 °C, 20 h)⁹ needed to remove the benzoyl protecting group gave a very poor yield in this step. These hydrolysis conditions will limit the use of this reaction in the case of amino acids with labile functional groups on the side chains. The trifluoromethyl ketone analogue of

- (1) Abbreviations: Aa, α-amino acid; Dpa, β,β-diphenylalanine; αNal, α-naphthylalanine; βNal, β-naphthylalanine; Fgl, fluorenylglycine; ψ(COCH₂), ketomethylene pseudopeptide bond; MMS, monomethyl succinate; Py, pyridine; TEA, triethylamine; pip, piperidine; Mtr, (4-methoxy-2,3,6-trimethylphenyl)sulfonyl; HOSu, N-hydroxysuccinimide; DCC, 1,3-dicyclohexylcarbodiimide; TFA, trifluoroacetic acid; EDC, 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride.
- (2) Claesson, G.; Aurell, L. Small Synthetic Peptides with Affinity for Proteases in Coagulation and Fibrinolysis, An Overview. *Ann. N.Y. Acad. Sci.* 1981, 370, 798–811.
- (3) Claesson, G.; Cheng, L.; Chino, N.; Deadman, J.; Elgandy, S. Inhibitors and Substrates of Thrombin. U.K. Patent Application 9024 129.0 (1991).
- (4) Bajusz, S.; Szell, E.; Bagdy, G.; Harvath, G.; Diozegi, D.; Fittler, Z.; Szabo, G.; Juhasz, A.; Szilagyi, G. Highly Active and Selective Anticoagulants: D-Phe-Pro-Arg-H, a Free Tripeptide Aldehyde Prone to Spontaneous Inactivation, and Its Stable N-Methyl Derivative, D-MePhe-Pro-Arg-H. *J. Med. Chem.* 1990, 33, 1729–1735.
- (5) Kettner, C.; Mersinger, L.; Knabbn, R. The Selective Inhibition of Thrombin by Peptides of Boroarginine. *J. Biol. Chem.* 1990, 265, 18289–18297.
- (6) Szelke, M.; Jones, D. M. Enzyme Inhibition. U.S. Patent 4772,686 (1987).
- (7) Scully, M. S.; Kakkar, V. V., unpublished results.
- (8) Dakin, H. D.; West, R. A General Reaction of Amino Acids. *J. Biol. Chem.* 1928, 78, 91–105.
- (9) Ewenson, A.; Lanfer, R.; Chorev, M.; Selinger, Z.; Gilon, C. Ketomethylene Pseudopeptide Analogues of Substance P: Synthesis and Biological Activity. *J. Med. Chem.* 1986, 29, 295–299.

* Present address: The Dyson Perrins Laboratory, Oxford University, South Parks Road, Oxford OX1 3QY, England.

Table I. Differences in Physical Data of Dipeptide **8a** and **8b**

compd	HPLC, min	¹ H NMR δ , ppm, NH	$[\alpha]^{25}_D$, deg	mp, °C
8a	16.9	5.66 (d, $J = 9$ Hz)	-139.0 (c 0.7, EtOH)	180–183
8a + 8b	14.5, 16.7	5.61 (d, $J = 9$ Hz) 5.55 (d, $J = 9$ Hz)		126–130
8b	14.6	5.55 (d, $J = 9$ Hz)	-21.0 (c 1.0, EtOH)	128–131

Table II. Thrombin Inhibitory Activity of Compound **1**

compd	K_i , μ M	TT, ^a μ M	APTT, ^b μ M
Szelke ^c	1.3	4.9	
1a	0.2	0.65	8.0
1b	1.7	7.5	100
1c	0.6		45
1d	13.5		
1e	11.6	90	
1f	2.28		
1g		50	

^aConcentration needed to double the human α -thrombin-induced clotting time of human plasma (control, 25 s).

^bConcentration needed to double the activated partial thromboplastin time of human plasma (auto-APTT reagent, general Diagnostic; control clotting time, 30 s). ^cD-Phe-Pro-Arg ψ (COCH₂)Gly-pip (data from ref 7).

The diastereomers Z-D-Dpa-Pro-OH (**8a**) and Z-L-Dpa-Pro-OH (**8b**) have been separated through fractionated recrystallization from ethyl acetate. One diastereomer comes out first as white crystals. A second crop, a mixture of diastereomers, was obtained by concentration of the mother liquid. The other isomer was obtained by addition of petroleum ether (bp: 60–80 °C). It was found that the first crop had Dpa in the D-configuration by crystallographic analysis, which will be reported in detail elsewhere. Both isomers were characterized by HPLC, ¹H NMR, and $[\alpha]^{25}_D$ (Table I), which indicate the high optical purity of both isomers (95% ee).

Results and Discussion

Table II shows the results of the in vitro inhibitory activity of compound **1**. Our earlier results have shown that in general tripeptides with the P₃ amino acid in the D-form have higher affinity to thrombin than the corresponding peptide with this amino acid in the L-form.² Compound **1a** from the first crop (**8a**) with D-Dpa is about 8 times more potent than **1b** from the third crop (**8b**), and about 3 times more potent than **1c** from a fully racemic starting material **2c**. Compound **1f** synthesized from D- β Nal is 5 times more active than compound **1e** from racemic **2e**. It is also shown in the table that substitution with D,L- α Nal or D,L-Fgl gives less potent thrombin inhibitors.

The Dakin-West reaction gives no stereoselectivity at the α -carbon of the arginine in the acylation reaction through an oxazalone intermediate (Scheme I). The evidence for racemization was obtained by HPLC analysis of both **1a** and **1b** as well as **1f**, which clearly indicated the existence of two isomers (retention times: **1a**, 14.73, 16.45 min; **1b**, 14.71, 16.63 min; **1f**, 11.60, 12.41 min). It is interesting to investigate which isomer is the most active thrombin inhibitor.

The crystal structure of PPACK-thrombin¹⁴ indicates that the loop Tyr-Pro-Pro-Trp (47–50) creates with Trp²²⁷(215), Leu⁹⁶(99), and Ile¹⁷⁹(174) a double hydrophobic

Table III. Selectivity of Compound **1a** for Thrombin Inhibition

	thrombin	plasmin	factor Xa	urokinase	kallikrein
K_i , μ M	0.2	157	149	494	199

pocket, a "D-pocket", and a "P-pocket", respectively. PPACK binds with D-Phe in the D-pocket and Pro in the P-pocket. The inhibitor Aa-Pro-Arg ψ (COCH₂)Gly-pip (**1**) might bind to thrombin in a similar mode with Aa in the D-pocket (S₃), Pro in the P-pocket (S₂), and the Arg side chain in the recognition pocket (S₁). Compound **1f** with D- β Nal has a better K_i than **1e** with racemic β Nal because the D-pocket prefers a D-amino acid in the P₃ position. In the same way, the D-pocket would prefer D-Dpa to L-Dpa. Compound **1a** has a K_i of 0.2 μ M and it doubles thrombin clotting time at only 3 times higher concentration. These values are about 7 times better than those of the corresponding D-Phe analogues.⁶ This might be explained by the extra phenyl group in Dpa producing higher affinity to the D-pocket, compared to D-Phe. The amino acid β Nal gives inhibitors roughly comparable to the Phe inhibitors while Fgl is not a good substitute for Phe. The rigid aromatic ring system in Fgl seems harder to accommodate, compared to the flexible ring in Dpa, preventing a good interaction with the thrombin binding site.

Table III shows the selectivity of the inhibitor **1a**. It is very poor inhibitor for plasmin, urokinase, kallikrein, and factor Xa. Thrombin has an extra loop, the "Try-Pro-Pro-Trp loop", not present in trypsin.¹⁴ The high specificity of **1a** for thrombin thus could be explained by the binding of Pro to the P-pocket and D-Dpa to the D-pocket. Preliminary in vivo testing (3–4-kg rabbit as the animal model) shows no observable side effect (change of blood pressure and accumulation of blood platelet in lungs) at a dose of 1 mg/kg.

Experimental Section

Melting points were measured on a Stuart capillary melting point apparatus and are uncorrected. TLC was carried out on precoated silica plates (Merk, F 254) in the following systems: A, chloroform-methanol (9:1); B, 1-butanol-acetic acid-ethyl acetate-water (1:1:1:1); C, ethyl acetate-ethanol-acetic acid (2:1:0.1); D, chloroform-methanol-acetic acid (95:5:3). The plates were visualized with the following reagent sprays: (I) ninhydrin (BDH), 0.1% in ethanol; (II) chlorine, dicarboxidine; (III) UV (254 nm); (III) iodine vapors. HPLC analysis was carried out on a LKB liquid chromatograph, using a LKB C₂/C₁₈ Superpac PepS column (4.0 \times 250 mm) and the following conditions: eluent, A = water containing 0.1% TFA; B = acetonitrile containing 0.1% TFA; gradient (in 25 min), (1) 50–90%, (2) 35–70%, (3) 10–50%; flow rate, 1.0 mL/min; detection, UV absorbance at 210 nm. ¹H and ¹³C NMR spectra were taken on a Bruker WM 250 instrument. Mass spectrometry was performed using a fast bombardment (FAB) ion source. Chromatography was carried on Merck flash silica gel.

EDC was purchased from Navobiochem. D- β Nal was purchased from Bachem [$[\alpha]_D = +16.0^\circ$ ($c = 0.4$, 50% AcOH)].

Preparation of the Anhydride of MMS. A solution of succinic anhydride (10.0 g, 0.1 mol), methanol (3.2 g, 0.1 mol), and DMAP (2 mg) in 50 mL of toluene was refluxing for 3.5 h and then cooled to room temperature. After evaporation of the solvent, crystals formed. The monomethyl succinate (MMS) was collected by filtration and washed with petroleum ether (12.5 g, 94%). Mp: 52–54 °C.

The MMS (0.32 g, 2.4 mmol) was dissolved in 20 mL of CH₂Cl₂ and 0.23 g of EDC (1.2 mmol) was added. The reaction was stirred for 20 min and then extracted with 2 \times 3 mL of ice-cold water, 3 mL of ice-cold 5% NaHCO₃, and 3 mL of ice-cold water. The organic layer was dried (MgSO₄) and filtered into a reaction flask for the following Dakin-West reaction, and the solvent was evaporated in vacuo.

Preparation of D,L-Dpa (6a). To a solution of potassium *tert*-butoxide (6.75 g, 0.06 mol) in *tert*-butyl alcohol (350 mL) was

(14) Banner, D. W.; Hadvary, P. Crystallographic Analysis at 3.0 Å Resolution of the Binding to Human Thrombin of Four Active Site-directed Inhibitors. *J. Biol. Chem.* 1991, 266, 20085–20094.

added, at room temperature under argon, ethyl acetamidocyanacetate (10 g, 0.059 mol). After the solution had become clear bromodiphenylmethane (14.55 g, 0.059 mol) was added. The mixture was stirred at 20 °C for 24 h and then evaporated under reduced pressure. The solid residue was treated with ethyl acetate (500 mL) and water (175 mL). The organic phase was dried (Na_2SO_4) and concentrated to give yellow crystals. The crystals were washed repeatedly with ether and dried to give ethyl acetamido(diphenylmethyl)cyanacetate (**5a**) (11.61 g, 58%). Mp: 181–185 °C.

Compound **5a** was mixed with hydrochloric acid (20%) and refluxed for 30 h. The reaction mixture was allowed to cool, and the crystals were collected, washed (ether), and dried to give **6a** as a salt of hydrogen chloride (7.82 g, 82%). R_f (solvent B): 0.67. $^1\text{H NMR } \delta$ (DMSO- d_6): 7.54–7.11 (10 H, m, $2\text{C}_6\text{H}_5$), 4.79 (1 H, d, αCH), 4.36 (1 H, d, βCH).

The following compounds **6** were synthesized as above.

D,L- α Nal (6b) (1.08 g, 36%). Mp: 198–201 °C. R_f (D): 0.10. $^1\text{H NMR } \delta$ (DMSO- d_6): 8.10–7.25 (7 H, m, C_{10}H_7), 3.47 (2 H, m, CH_2).

D,L- β Nal (6c) (2.89 g, 79%). $^1\text{H NMR } \delta$ (DMSO- d_6): 7.79–7.27 (7 H, m, C_{10}H_7), 4.48 (1 H, m, αCH), 3.35 (2 H, d, CH_2).

D,L-Fgl (6d) (4.76 g, 72%). $^1\text{H NMR } \delta$ (D_2O): 7.86–7.37 (8 H, m, C_{13}H_9), 5.00 (1 H, m, αCH), 4.66 (1 H, d, βCH).

Preparation of Boc-D,L-Dpa (7a). To a solution of **6a** (2.78 g, 10 mmol) in a mixture of dioxane (20 mL), water (10 mL), and 1 N NaOH (20 mL), cooled to 0 °C and stirred, was added *tert*-butylpyrrocarbonate (2.4 g, 11 mmol), stirring was continued at room temperature for 2 h. The solution was concentrated in vacuo to 20 mL, cooled in an ice-water bath, covered with a layer of ethyl acetate (30 mL), and acidified to pH 2–3 with dilute solution of KH_2SO_4 . The aqueous layer was extracted with ethyl acetate, and the combined organic layers were dried (MgSO_4) and evaporated to dryness to give **7a** as a solid (3.38 g, 90%). Mp: 127–129 °C. $^1\text{H NMR } \delta$ (DMSO- d_6): 7.27 (19 H, m, $2\text{C}_6\text{H}_5$), 5.07 (1 H, d, NH), 4.86 (1 H, d, αCH), 4.49 (1 H, d, βCH), 1.36 (9 H, s, $t\text{-C}_4\text{H}_9$).

The following compounds **7** were synthesized as above.

Boc-D,L- α Nal (7c) (1.23 g, 82%). Mp: 148–151 °C. R_f (D): 0.54. $^1\text{H NMR } \delta$ (DMSO- d_6): 8.10–7.25 (7 H, m, C_{10}H_7), 5.12 (1 H, d, NH), 4.83 (1 H, m, CH), 3.38 (2 H, d, CH_2), 1.36 (9 H, s, $t\text{-C}_4\text{H}_9$).

Boc-D,L- β Nal (7d) (1.92 g, 61%). $^1\text{H NMR } \delta$ (CDCl_3): 7.75–7.25 (7 H, m, C_{10}H_7), 5.23 (1 H, d, NH), 4.74 (1 H, m, CH), 3.31 (2 H, d, CH_2), 1.36 (9 H, s, $t\text{-C}_4\text{H}_9$).

Boc-D,L-Fgl (7f) (2.90 g, 85%). $^1\text{H NMR } \delta$ (CDCl_3): 7.74–7.23 (8 H, m, C_{13}H_9), 5.62 (1 H, d, NH), 5.01 (1 H, m, αCH), 4.08 (1 H, d, βCH), 1.37 (9 H, s, $t\text{-C}_4\text{H}_9$).

Z-D,L-Dpa (7b). To a solution of **6a** (2.45 g, 10 mmol) in water (10 mL) and dioxane (10 mL) in the presence of triethylamine (1.7 mL, 12.2 mmol) was added *N*-[(benzyloxycarbonyl)oxy]succinimide (2.54 g, 10.2 mmol) at room temperature and the mixture was stirred overnight. The reaction mixture was poured into 50 mL of water and the product was extracted with 100 mL of chloroform, washed with 1 N HCl then water, and dried (Na_2SO_4). After removal of the chloroform the residue was crystallized from ethyl acetate and petroleum ether (bp: 40–60 °C) (3.40 g, 90%) as white solid. Mp: 214–217 °C. $^1\text{H NMR } \delta$ (DMSO- d_6): 7.32–7.12 (10 H, m, $2\text{C}_6\text{H}_5$), 5.56 (1 H, d, NH), 5.27 (1 H, d, αCH), 5.02 (2 H, s, OCH_2), 4.41 (1 H, d, βCH).

Z-D- β Nal (7e). Z-OSu was used (1.15 g, 95%). $^1\text{H NMR } \delta$ (CDCl_3): 7.85–7.40 (7 H, m, C_{10}H_7), 7.29 (5 H, s, C_6H_5), 5.20 (1 H, d, NH), 5.08 (2 H, s, OCH_2), 4.77 (1 H, m, CH), 3.32 (2 H, d, CH_2).

Preparation of Boc-D,L-Dpa-ProOH (8c). A solution of **7a** (3.41 g, 10 mmol) and *N*-hydroxysuccinimide (1.15 g, 10 mmol) in dry 1,2-dimethoxyethane (30 mL) was cooled in an ice-water bath and DCC (2.06 g, 10 mmol) was added with stirring. Further stirring was continued for 4 h. The formed DCU was filtrated off and the solvent was evaporated in vacuo. The activate product was obtained through recrystallization from dichloromethane and petroleum ether (bp: 60–80 °C) (4.15 g, 94%). Mp: 185–187 °C.

To a solution of proline (0.78 g, 6.75 mmol) and sodium hydrogen carbonate (0.57 g, 6.75 mmol) in H_2O (10 mL) was added Boc-D,L-Dpa-OSu (1.97 g, 4.5 mmol) in 10 mL of 1,2-dimethoxyethane at room temperature with stirring. After 3 h, the

organic solvent was evaporated. The aqueous solution was acidified with 1 N HCl to pH 2; a white solid formed and was collected with filtration, washed with ether, and dried (1.82 g, 92%). Mp: 94–96 °C. $^1\text{H NMR } \delta$ (CDCl_3): 7.37–7.17 (10 H, m, $2\text{C}_6\text{H}_5$), 5.12 (1 H, m, NH), 4.38 (1 H, dd, Dpa αCH), 4.16 (1 H, d, Dpa βCH), 3.85 (1 H, m, Pro CH), 1.35 (9 H, s, $t\text{-C}_4\text{H}_9$).

Z-D,L-Dpa-ProOH (8a + 8b) (1.98 g, 93%). Mp: 126–130 °C.

Z-D-Dpa-ProOH (8a) (0.70 g). Mp: 180–183 °C (obtained by recrystallization from ethyl acetate). HPLC (2): 16.9 min. $^1\text{H NMR } \delta$ (CDCl_3): 7.38–7.17 (15 H, m, $3\text{C}_6\text{H}_5$), 5.66 (1 H, d, NH), 5.26 (1 H, dd, Dpa αCH), 5.00 (2 H, m, OCH_2), 4.40 (1 H, d, Dpa βCH), 3.81 (1 H, t, Pro CH), 2.80 (2 H, m, NCH_2), 2.10–1.10 (4 H, m, 2CH_2). MS m/z (FAB): 473 (M + H), 495 (M + Na).

Z-L-Dpa-ProOH (8b) (0.54 g). Mp: 128–131 °C (obtained by recrystallization from ethyl acetate–petroleum ether). HPLC (2): 14.6 min. $^1\text{H NMR } \delta$ (CDCl_3): 7.43–7.10 (15 H, m, $3\text{C}_6\text{H}_5$), 5.55 (1 H, d, NH), 5.23 (1 H, dd, Dpa αCH), 5.04 (2 H, m, OCH_2), 4.45 (1 H, d, Dpa βCH), 3.78 (1 H, m, Pro CH), 2.90 (2 H, m, NCH_2), 2.25–1.10 (4 H, m, 2CH_2). MS m/z (FAB): 473 (M + H), 495 (M + Na).

Boc-D,L- α Nal-ProOH (8d) (1.35 g, 91%). Mp: 70–78 °C. R_f (D): 0.58. $^1\text{H NMR } \delta$ (CDCl_3): 8.07–7.30 (7 H, m, C_{10}H_7), 5.24 (1 H, m, NH), 4.85 (1 H, m, Nal CH), 3.75 (1 H, m, Pro CH), 3.47 (2 H, m, Nal CH_2), 1.36 (9 H, s, $t\text{-C}_4\text{H}_9$).

Boc-D,L- β Nal-ProOH (8e) (0.5 g, 89%). $^1\text{H NMR } \delta$ (CDCl_3): 7.79–7.25 (7 H, m, C_{10}H_7), 4.56 (1 H, Nal CH), 3.66 (2 H, m, Nal CH_2), 1.31 (9 H, s, $t\text{-C}_4\text{H}_9$).

Z-D- β Nal-ProOH (8f) (1.14 g, 89%). HPLC (1): 11.3 min. $^1\text{H NMR } \delta$ (CDCl_3): 7.85–7.40 (7 H, m, C_{10}H_7), 7.29 (5 H, s, C_6H_5), 5.21 (1 H, d, NH), 5.08 (2 H, m, OCH_2), 4.77 (1 H, m, Nal CH), 3.79 (1 H, m, Pro CH), 3.30 (2 H, m, Nal CH_2).

Boc-D,L-Fgl-ProOH (8g) (2.01 g, 92%). HPLC (1): 6.5, 7.1 min. $^1\text{H NMR } \delta$ (CDCl_3): 7.74–7.23 (8 H, m, C_{13}H_9), 5.89 (1 H, m, NH), 5.03 (1 H, m, Fgl αCH), 4.11 (1 H, m, Fgl βCH), 3.75 (1 H, m, Pro CH), 1.37 (9 H, s, $t\text{-C}_4\text{H}_9$).

Preparation of Boc-D,L-Dpa-Pro-Arg(Mtr)OH (2c). To a solution of **8c** (0.44 g, 1.0 mmol) and HOSu (0.12 g, 1.0 mmol) in 20 mL of 1,2-dimethoxyethane was added DCC (0.21 g, 1.0 mmol) with cooling over an ice-water bath, and then stirring was continued at room temperature for 3 h. The DCU was filtered off and the solvent was evaporated to give an oily crude activate dipeptide. To a solution of H-Arg(Mtr)OH (0.42 g, 1.1 mmol) and Et_3N (1.1 mmol) in 30 mL of DMF was added the solution of Boc-D,L-Dpa-Pro-OSu obtained above in 15 mL of 1,2-dimethoxyethane with cooling over an ice-water bath. The reaction mixture was stirred at room temperature overnight. The solvent was evaporated in vacuo. The residue was dissolved in methanol and 20 mL of water. The solution was acidified with 1 N HCl to pH 2. Methanol was removed in vacuo to give a white precipitate, which was collected through filtration and dried in vacuo (0.70 g, 88%). $^1\text{H NMR } \delta$ (CDCl_3): 7.34–7.20 (10 H, m, $2\text{C}_6\text{H}_5$), 6.51 (1 H, s, CH), 6.37 (3 H, b, 3 NH), 5.42 (1 H, d, NH), 5.20 (1 H, d, NH), 4.81 (1 H, m, Dpa αCH), 4.35 (1 H, d, Dpa βCH), 4.20 (1 H, d, Arg CH), 3.81 (3 H, s, OCH_3), 3.75 (1 H, m, Pro CH), 2.68 (3 H, d, CH_3), 2.60 (3 H, d, CH_3), 2.11 (3 H, s, CH_3), 1.28 (9 H, d, $t\text{-C}_4\text{H}_9$), 3.52–1.10 (12 H, m, 6 CH_2).

Z-D-Dpa-Pro-Arg(Mtr)OH (2a) (0.77 g, 91%). $^1\text{H NMR } \delta$ (CDCl_3): 7.47 (1 H, d, NH), 7.33–7.18 (15 H, m, $3\text{C}_6\text{H}_5$), 6.48 (1 H, s, CH), 6.32 (3 H, b, 3 NH), 5.83 (1 H, d, NH), 5.02 (2 H, m, OCH_2), 4.83 (1 H, d, Dpa αCH), 4.35 (1 H, d, Dpa βCH), 4.19 (1 H, d, Arg CH), 3.78 (3 H, s, OCH_3), 3.74 (1 H, m, Pro CH), 2.65 (3 H, s, CH_3), 2.57 (3 H, s, CH_3), 2.08 (3 H, s, CH_3), 3.55–1.00 (12 H, m, 6 CH_2).

Z-L-Dpa-Pro-Arg(Mtr)OH (2b) (0.82 g, 95%). $^1\text{H NMR } \delta$ (CDCl_3): 7.34–7.20 (15 H, m, $3\text{C}_6\text{H}_5$), 6.48 (1 H, s, CH), 5.78 (1 H, d, NH), 5.02 (2 H, m, OCH_2), 4.80 (1 H, d, Dpa αCH), 4.38 (1 H, d, Dpa βCH), 4.19 (1 H, d, Arg CH), 3.78 (3 H, s, OCH_3), 3.74 (1 H, m, Pro CH), 2.65 (3 H, s, CH_3), 2.56 (3 H, s, CH_3), 2.09 (3 H, s, CH_3), 3.55–1.10 (12 H, m, 6 CH_2).

Boc-D,L- α Nal-Pro-Arg(Mtr)-OH (2d) (0.72 g, 92%). R_f (C): 0.51. $^1\text{H NMR } \delta$ (CDCl_3): 8.07–7.30 (7 H, m, C_{10}H_7), 6.48 (1 H, d, CH), 6.40 (3 H, b, 3 NH), 4.64 (1 H, m, Nal CH), 3.82 (1 H, m, Arg CH), 3.79 (3 H, s, OCH_3), 3.74 (1 H, m, Pro CH), 3.49 (2 H, m, Nal CH_2), 2.67 (3 H, s, CH_3), 2.59 (3 H, s, CH_3), 2.10 (3 H, s, CH_3), 1.39 (9 H, m, $t\text{-C}_4\text{H}_9$).

Boc-D,L-βNal-Pro-Arg(Mtr)-OH (2e) (0.29 g, 88%). ¹H NMR δ (CDCl₃): 7.75–7.25 (7 H, m, C₁₀H₇), 6.51 (1 H, s, CH), 6.47 (3 H, b, 3 NH), 4.75 (1 H, m, Nal CH), 4.21 (1 H, d, Arg CH), 3.81 (3 H, s, OCH₃), 3.74 (1 H, m, Pro CH), 3.47 (2 H, m, Nal CH₂), 2.63 (3 H, m, CH₃), 2.56 (3 H, m, CH₃), 2.09 (3 H, m, CH₃), 1.37 (9 H, m, *t*-C₄H₉), 3.55–1.10 (12 H, m, 6 CH₂). MS *m/z* (FAB): 804 (M + Na).

Z-D-βNal-Pro-Arg(Mtr)-OH (2f) (0.40 g, 97%). ¹H NMR δ (CDCl₃): 7.86–7.41 (7 H, m, C₁₀H₇), 7.29 (5 H, s, C₆H₅), 6.48 (1 H, s, CH), 5.02 (2 H, m, OCH₂), 4.76 (1 H, m, Nal CH), 4.21 (1 H, d, Arg CH), 3.75 (3 H, s, OCH₃), 3.74 (1 H, m, Pro CH), 3.46 (2 H, m, Nal CH₂), 2.65 (3 H, s, CH₃), 2.57 (3 H, s, CH₃), 2.08 (3 H, s, CH₃), 3.50–1.00 (12 H, m, 6 CH₂).

Boc-D,L-Fgl-Pro-Arg(Mtr)-OH (2g) (0.71 g, 88%). *R_f* (C): 0.61. ¹H NMR δ (CDCl₃): 7.74–7.23 (8 H, m, C₁₃H₉), 6.51 (1 H, s, CH), 4.94 (1 H, m, Fgl αCH), 4.23 (1 H, m, Arg CH), 4.11 (1 H, m, Fgl βCH), 3.78 (3 H, s, OCH₃), 3.75 (1 H, m, Pro CH), 2.64 (3 H, m, CH₃), 2.56 (3 H, m, CH₃), 2.10 (3 H, m, CH₃), 1.38 (9 H, m, *t*-C₄H₉), 3.55–1.00 (12 H, m, 6 CH₂).

Preparation of Boc-D,L-Dpa-Pro-Arg(Mtr)ψ(COCH₂)Gly-OMe (3c). Boc-D,L-Dpa-Pro-Arg(Mtr)-OH (0.12 g, 0.15 mmol) was added to the anhydride of MMS (7 equiv, 1.05 mmol). Et₃N (0.33 mmol), DMAP (2.0 mg), and pyridine (0.13 mL) were added. The reaction mixture was stirred over a 45–50 °C water bath. After the reaction mixture was stirred for 1 h, 10 mL of 5% NaHCO₃ was added and the resultant mixture was stirred for an additional 30 min. The product was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried (Na₂SO₄), and concentrated to dryness. The product was isolated by a flash silica gel column (2% methanol in CHCl₃ as eluent) to give **3c** (120 mg, 95%). ¹H NMR δ (CDCl₃): 7.35–7.21 (10 H, m, 2 C₆H₅), 6.52 (1 H, s, CH), 6.15 (1 H, m, NH), 4.98 (1 H, m, Dpa αCH), 4.54 (1 H, m, Arg CH), 4.35 (1 H, m, Dpa βCH), 4.17 (1 H, m, Pro CH), 3.81 (3 H, m, Mtr OCH₃), 3.67 (3 H, m, OCH₂), 2.72 (3 H, m, Mtr CH₃), 2.64 (3 H, m, Mtr CH₃), 2.12 (3 H, s, Mtr CH₃), 1.25 (9 H, m, *t*-C₄H₉), 3.45–1.10 (16 H, m, 8 CH₂). MS *m/z* (FAB): 877 (M⁺).

Z-D-Dpa-Pro-Arg(Mtr)ψ(COCH₂)Gly-OMe (3a) (134 mg, 98%). ¹H NMR δ (CDCl₃): 7.40–7.22 (15 H, m, 3 C₆H₅), 6.50 (1 H, d, CH), 5.98 (1 H, d, NH), 5.01 (1 H, m, Dpa αCH), 4.97 (2 H, m, OCH₂), 4.42 (1 H, m, Arg CH), 4.28 (1 H, m, Dpa βCH), 4.07 (1 H, m, Pro CH), 3.80 (3 H, d, Mtr OCH₃), 3.68 (3 H, d, OCH₂), 2.73 (3 H, m, Mtr CH₃), 2.64 (3 H, m, Mtr CH₃), 2.12 (3 H, d, Mtr CH₃), 3.45–1.10 (16 H, m, 8 CH₂).

Z-L-Dpa-Pro-Arg(Mtr)ψ(COCH₂)Gly-OMe (3b) (127 mg, 92%). ¹H NMR δ (CDCl₃): 7.26–7.21 (15 H, m, 3 C₆H₅), 6.55 (1 H, m, NH), 6.51 (1 H, d, Mtr CH), 5.32 (1 H, m, NH), 5.02 (1 H, m, Dpa αCH), 4.97 (2 H, m, OCH₂), 4.46 (1 H, m, Arg CH), 4.35 (1 H, m, Dpa βCH), 4.08 (1 H, m, Pro CH), 3.81 (3 H, d, Mtr OCH₃), 3.68 (3 H, d, OCH₂), 2.70 (3 H, m, Mtr CH₃), 2.64 (3 H, m, Mtr CH₃), 2.12 (3 H, s, Mtr CH₃), 3.4–1.10 (16 H, m, 8 CH₂).

Boc-D,L-αNal-Pro-Arg(Mtr)ψ(COCH₂)Gly-OMe (3d) (135 mg, 94%). Mp: 71–74 °C. ¹H NMR δ (CDCl₃): 8.15–7.33 (7 H, m, C₁₀H₇), 6.51 (1 H, s, CH), 6.35–6.03 (3 H, b, 3 NH), 5.25 (1 H, m, Nal CH), 4.45 (1 H, m, Arg CH), 4.14 (1 H, m, Pro CH), 3.79 (3 H, s, Mtr OCH₃), 3.67 (3 H, m, OCH₂), 3.62 (2 H, m, Nal CH₂), 2.68 (3 H, m, Mtr CH₃), 2.61 (3 H, m, Mtr CH₃), 2.11 (3 H, m, Mtr CH₃), 1.37 (9 H, d, *t*-Bu), 3.47–1.10 (16 H, m, 8 CH₂).

Boc-D,L-βNal-Pro-Arg(Mtr)ψ(COCH₂)Gly-OMe (3e) (121 mg, 71%). *R_f* (A): 0.39. ¹H NMR δ (CDCl₃): 7.75–7.23 (7 H, m, C₁₀H₇), 6.55 (1 H, d, NH), 6.51 (1 H, d, Mtr CH), 6.23 (3 H, b, 3 NH), 4.74 (1 H, m, Nal CH), 4.41 (1 H, m, Arg CH), 4.07 (1 H, m, Pro CH), 3.81 (3 H, s, Mtr OCH₃), 3.65 (3 H, m, OCH₂), 3.46 (2 H, m, Nal CH₂), 2.68 (3 H, m, Mtr CH₃), 2.61 (3 H, m, Mtr CH₃), 2.11 (3 H, s, Mtr CH₃), 1.38 (9 H, m, *t*-C₄H₉), 3.50–1.10 (16 H, m, 8 CH₂).

Z-D-βNal-Pro-Arg(Mtr)ψ(COCH₂)Gly-OMe (3f) (122 mg, 92%). ¹H NMR δ (CDCl₃): 7.85–7.42 (7 H, m, C₁₀H₇), 7.28 (5 H, s, C₆H₅), 6.49 (1 H, d, CH), 5.02 (2 H, m, OCH₂), 4.76 (1 H, m, Nal CH), 4.45 (1 H, m, Arg CH), 4.11 (1 H, m, Pro CH), 3.81 (3 H, d, Mtr OCH₃), 3.69 (3 H, d, OCH₂), 3.49 (2 H, m, Nal CH₂), 2.70 (3 H, m, Mtr CH₃), 2.64 (3 H, m, Mtr CH₃), 2.12 (3 H, d, Mtr CH₃), 3.48–1.10 (16 H, m, 8 CH₂).

Boc-D,L-Fgl-Pro-Arg(Mtr)ψ(COCH₂)Gly-OMe (3g) (125 mg, 95%). ¹H NMR (CDCl₃): 7.80–7.20 (8 H, m, C₁₃H₉), 6.52 (1 H, d, NH), 6.48 (1 H, d, CH), 6.20 (3 H, b, 3 NH), 5.08 (1 H, m, Fgl

αCH), 4.61 (1 H, m, Fgl βCH), 4.47 (1 H, m, Arg CH), 4.11 (1 H, m, Pro CH), 3.80 (3 H, m, Mtr OCH₃), 3.65 (3 H, m, OCH₂), 2.67 (3 H, m, Mtr CH₃), 2.61 (3 H, m, Mtr CH₃), 2.12 (3 H, m, Mtr CH₃), 1.22 (9 H, m, *t*-C₄H₉), 3.50–1.10 (16 H, m, 8 CH₂).

Preparation of Boc-D,L-Dpa-Arg(Mtr)ψ(COCH₂)Gly-pip (4c). To a solution of **3c** (0.1 g, 0.11 mmol) in 10 mL of methanol cooled over an ice-water bath was added 1 N NaOH (2 equiv) with stirring. After stirring at room temperature for 2.5 h, it was brought to pH 7 with 1 N HCl. Methanol was removed in vacuo, and the aqueous solution was extracted with AcOEt and dried (MgSO₄). A crude solid was obtained after concentration to dryness.

To the solution of the crude solid and HOSu (13 mg, 0.11 mmol) in 20 mL of 1,2-dimethoxyethane was added DCC (23 mg, 0.11 mmol) with cooling. The mixture was stirred at room temperature for 20 h and then piperidine (19 mg, 0.22 mmol) was added with cooling. It was stirred at room temperature for 3 h. The solvent was evaporated in vacuo and the residue was purified through a flash silica gel column (CHCl₃ and then 2% methanol in CHCl₃ as eluent) to give **4c** (86 mg, 84%). Mp: 103–107 °C. ¹H NMR δ (CDCl₃): 7.34–7.21 (10 H, m, 2 C₆H₅), 6.51 (1 H, m, Mtr CH), 6.34 (1 H, m, NH), 6.18 (3 H, m, 3 NH), 5.99 (1 H, m, NH), 5.01 (1 H, m, Dpa αCH), 4.51 (1 H, Arg CH), 4.32 (1 H, m, Dpa βCH), 4.21 (1 H, m, Pro CH), 3.80 (3 H, m, Mtr OCH₃), 3.43 (4 H, m, pipCH₂), 2.71 (3 H, m, Mtr CH₃), 2.63 (3 H, m, Mtr CH₃), 2.12 (3 H, m, Mtr CH₃), 1.27 (9 H, m, *t*-C₄H₉), 3.28–1.10 (22 H, m, 11 CH₂). MS *m/z* (FAB): 930 (M⁺).

Z-D-Dpa-Arg(Mtr)ψ(COCH₂)Gly-pip (4a) (78 mg, 81%). *R_f* (A): 0.60. ¹H NMR δ (CDCl₃): 7.35–7.22 (15 H, m, 3 C₆H₅), 6.50 (1 H, d, CH), 6.30 (1 H, d, NH), 5.96 (3 H, b, 3 NH), 5.28 (1 H, d, NH), 4.97 (1 H, m, Dpa αCH), 4.85 (2 H, m, OCH₂), 4.54 (1 H, m, Arg CH), 4.37 (1 H, m, Dpa βCH), 4.28 (1 H, m, Pro CH), 3.81 (3 H, d, Mtr OCH₃), 3.36 (4 H, m, pip NCH₂), 2.69 (3 H, d, Mtr CH₃), 3.63 (3 H, d, Mtr CH₃), 2.11 (3 H, d, Mtr CH₃), 3.25–1.10 (22 H, m, 11 CH₂).

Z-L-Dpa-Arg(Mtr)ψ(COCH₂)Gly-pip (4b) (80 mg, 75%). ¹H NMR δ (CDCl₃): 7.35–7.21 (15 H, m, 3 C₆H₅), 6.51 (1 H, d, CH), 5.25 (1 H, d, NH), 4.94 (1 H, m, Dpa αCH), 4.85 (1 H, m, OCH₂), 4.53 (1 H, m, Arg CH), 4.38 (1 H, m, Dpa βCH), 4.29 (1 H, m, Pro CH), 3.81 (3 H, d, Mtr OCH₃), 2.69 (3 H, d, Mtr CH₃), 3.62 (3 H, d, Mtr CH₃), 2.10 (CH₃, d, Mtr CH₃), 3.36–1.10 (26 H, m, 13 CH₂).

Boc-D,L-αNal-Pro-Arg(Mtr)ψ(COCH₂)Gly-pip (4d) (107 mg, 88%). ¹H NMR δ (CDCl₃): 8.13–7.32 (7 H, m, C₁₀H₇), 6.51 (1 H, s, CH), 6.21 (3 H, m, 3 NH), 5.26 (1 H, m, Nal CH), 4.64 (1 H, m, Arg CH), 4.23 (1 H, m, Pro CH), 4.05 (3 H, m, Mtr OCH₃), 3.46 (2 H, m, Nal CH₂), 3.42 (4 H, m, pip NCH₂), 2.70 (3 H, m, Mtr CH₃), 2.62 (3 H, m, Mtr CH₃), 2.12 (3 H, m, Mtr CH₃), 1.27 (9 H, m, *t*-C₄H₉), 3.27–1.11 (22 H, m, 11 CH₂).

Boc-D,L-βNal-Pro-Arg(Mtr)ψ(COCH₂)Gly-pip (4e) (90 mg, 62%). ¹H NMR δ (CDCl₃): 7.75–7.23 (7 H, m, C₁₀H₇), 6.51 (1 H, d, CH), 6.23 (3 H, b, 3 NH), 5.15 (1 H, m, Nal CH), 4.64 (1 H, m, Arg CH), 4.11 (1 H, m, Pro CH), 3.95 (3 H, m, Mtr OCH₃), 3.47 (2 H, m, Nal CH₂), 2.71 (3 H, m, Mtr CH₃), 2.64 (3 H, m, Mtr CH₃), 2.15 (3 H, m, Mtr CH₃), 1.26 (9 H, m, *t*-C₄H₉), 3.38–1.10 (26 H, m, 13 CH₂).

Z-D-βNal-Pro-Arg(Mtr)ψ(COCH₂)Gly-pip (4f) (63 mg, 76%). ¹H NMR δ (CDCl₃): 7.85–7.41 (7 H, m, C₁₀H₇), 7.28 (5 H, s, C₆H₅), 6.51 (1 H, d, CH), 5.02 (2 H, m, OCH₂), 4.76 (1 H, m, Nal CH), 4.64 (1 H, m, Arg CH), 4.14 (1 H, m, Pro CH), 3.81 (3 H, d, Mtr OCH₃), 3.46 (2 H, m, Nal CH₂), 2.71 (3 H, m, Mtr CH₃), 2.65 (3 H, m, Mtr CH₃), 2.11 (3 H, m, Mtr CH₃), 3.45–1.11 (26 H, m, 13 CH₂).

Boc-D,L-Fgl-Pro-Arg(Mtr)ψ(COCH₂)Gly-pip (4g) (89 mg, 87%). ¹H NMR δ (CDCl₃): 7.74–7.13 (8 H, m, C₁₃H₉), 6.50 (1 H, m, CH), 6.19 (3 H, m, 3 NH), 5.06 (1 H, m, Fgl αCH), 4.76 (1 H, m, Fgl βCH), 4.64 (1 H, m, Arg CH), 4.53 (1 H, m, Pro CH), 4.13 (3 H, m, Mtr OCH₃), 3.44 (4 H, m, pip CH₂), 2.75 (3 H, m, Mtr CH₃), 2.65 (3 H, m, Mtr CH₃), 2.12 (3 H, m, Mtr CH₃), 1.27 (9 H, m, *t*-C₄H₉), 3.25–1.10 (22 H, m, 11 CH₂).

Preparation of D,L-Dpa-Pro-Argψ(COCH₂)Gly-pip (1c). To a mixture of 50 mg of compound **4c** and thioanisole (0.1 mL) cooled over an ice-water bath was added TFA (0.9 mL) with stirring. The reaction mixture was stirred at 0 °C for 30 min and at room temperature for 3 h. TFA was removed under reduced pressure. The residue was triturated with ether. The solid (**1c**)

(30 mg, 68%) was obtained by filtration, followed by washing with ether thoroughly, and dried. Mp: 121–126 °C. R_f (B): 0.46. HPLC (3): 14.8, 15.3 min. $^1\text{H NMR } \delta$ (CDCl_3): 7.55–7.10 (10 H, m, 2 C_6H_5), 4.98 (1 H, m, Dpa αCH), 4.53 (1 H, m, Arg CH), 4.32 (1 H, m, Dpa βCH), 4.20 (1 H, m, Pro CH), 3.38–1.10 (26 H, m, 13 CH_2). MS m/z (FAB): 618 (M^{++}).

D-Dpa-Pro-Arg ψ (COCH₂)Gly-pip (1a) (30 mg, 75%). Mp: 146–151 °C. R_f (B): 0.41. HPLC (3): 14.73, 16.54 min. $^1\text{H NMR } \delta$ (CDCl_3): 7.55–7.10 (10 H, m, 2 C_6H_5), 7.10–6.10 (4 H, m, guanidino H), 4.98 (1 H, m, Dpa αCH), 4.53 (1 H, m, Arg CH), 4.32 (1 H, m, Dpa βCH), 4.20 (1 H, m, Pro CH), 3.38–1.15 (26 H, m, 13 CH_2). MS m/z (FAB): 619 (M + H), 641 (M + Na). Anal. ($\text{C}_{34}\text{H}_{47}\text{N}_7\text{O}_4 \cdot 2\text{TFA} \cdot 4\text{H}_2\text{O}$): C, H, N.

L-Dpa-Pro-Arg ψ (COCH₂)Gly-pip (1b) (30 mg, 43%). Mp: 136–140 °C. R_f (B): 0.41. $^1\text{H NMR } \delta$ (CDCl_3): 7.43–7.10 (10 H, m, 2 C_6H_5), 4.99 (1 H, m, Dpa αCH), 4.56 (1 H, m, Arg CH), 4.35 (1 H, m, Dpa βCH), 4.20 (1 H, m, Pro CH), 3.40–1.15 (26 H, m, 13 CH_2). MS m/z (FAB): 619 (M + H). Anal. ($\text{C}_{34}\text{H}_{47}\text{N}_7\text{O}_4 \cdot 2\text{CF}_3\text{CO}_2\text{H} \cdot 3.5\text{H}_2\text{O}$): C, H, N.

D,L- α Nal-Pro-Arg ψ (COCH₂)Gly-pip (1d) (72 mg, 82%). Mp: 123–127 °C. HPLC (3): 13.33, 13.75 min. $^1\text{H NMR } \delta$ (CDCl_3): 8.15–7.25 (7 H, m, C_{10}H_7), 5.26 (1 H, m, Nal CH), 4.64 (1 H, m, Arg αCH), 4.23 (1 H, m, Pro αCH), 3.46 (2 H, m, Nal CH_2), 3.42–1.10 (26 H, m, 13 CH_2). MS m/z (FAB): 592 (M^{++}). Anal. ($\text{C}_{32}\text{H}_{45}\text{N}_7\text{O}_4 \cdot 2\text{TFA} \cdot 3\text{H}_2\text{O}$): C, H, N.

D,L- β Nal-Pro-Arg ψ (COCH₂)Gly-pip (1e) (35 mg, 30%). MS m/z (FAB): 592 (M^{++}). Anal. ($\text{C}_{32}\text{H}_{45}\text{N}_7\text{O}_4 \cdot 2\text{TFA} \cdot 3.5\text{H}_2\text{O}$): C, H, N.

D- β Nal-Pro-Arg ψ (COCH₂)Gly-pip (1f) (28 mg, 68%). HPLC (3): 11.6, 12.4 min. $^1\text{H NMR } \delta$ (CDCl_3): 7.70–7.21 (7 H, m, C_{10}H_7),

4.78 (1 H, m, Nal CH), 4.46 (1 H, m, Arg CH), 4.18 (1 H, m, Pro CH), 3.47 (2 H, m, Nal CH_2), 3.40–1.10 (26 H, m, 13 CH_2). MS m/z (FAB): 593 (M + H). Anal. ($\text{C}_{32}\text{H}_{45}\text{N}_7\text{O}_4 \cdot 2\text{TFA} \cdot 4\text{H}_2\text{O}$): C, H, N.

D,L-Fgl-Pro-Arg ψ (COCH₂)Gly-pip (1g) (59 mg, 81%). R_f (B): 0.46. $^1\text{H NMR } \delta$ (CDCl_3): 7.77–7.15 (8 H, m, C_{13}H_8), 5.04 (1 H, m, Fgl αCH), 4.76 (1 H, m, Arg CH), 4.64 (1 H, m, Fgl βCH), 4.53 (1 H, m, Pro CH), 3.45–1.05 (26 H, m, 13 CH_2). MS m/z (FAB): 617 (M^{++}). Anal. ($\text{C}_{34}\text{H}_{45}\text{N}_7\text{O}_4 \cdot 2\text{TFA} \cdot 3.5\text{H}_2\text{O}$): C, H, N.

Enzymatic Assay.¹⁵ Kinetic studies were made in 0.1 M sodium phosphate buffer containing 0.2 M NaCl, 0.5% polyethylene glycol 6000, and 0.02% sodium azide at pH 7.5. The assays were performed in the presence or absence of inhibitor at a concentration sufficient to give approximately 50% inhibition at a single concentration of substrate S-2238 (10 μM). The assay was carried out with a range of substrate concentrations at and around the K_m for substrate/thrombin (20–5 μM). The final concentration of human α -thrombin¹⁶ used was 0.19 nM, and the assays were carried out at 37 °C. The inhibition constant (K_i) was calculated from a Lineweaver–Burk plot.

(15) Scully, M. F.; Kakkar, V. V. Semimicro and Automated Methods for the Determination of Thrombin, Antithrombin and Heparin Cofactor Using Chromagenic Substrate H-D-Phe-Pip-Arg-pNa. *Clin. Chem. Acta* 1977, 79, 595–602.

(16) The source of thrombin: Dr. J. M. Freysinnet, University of Strasbourg, prepared according to Boissel, J.-P.; Bonniec, M. J.; Labie, D.; Elion, J. Covalent Structures of β and γ Autolytic Derivatives of Human α -Thrombin. *J. Biol. Chem.* 1984, 259, 5691–5697.

3',3'-Difluoro-3'-deoxythymidine: Comparison of Anti-HIV Activity to 3'-Fluoro-3'-deoxythymidine

Donald E. Bergstrom,^{*,1a} Andrew W. Mott,² Erik De Clercq,^{1b} Jan Balzarini,^{1b} and Daniel J. Swartling^{1a}

Department of Medicinal Chemistry and Pharmacognosy, Purdue University, West Lafayette, Indiana 47907, and The Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium. Received November 18, 1991

3',3'-Difluoro-3'-deoxythymidine (**3**) has been synthesized in four steps from thymidine, and characterized by $^1\text{H NMR}$ and NOE experiments. The J_{HF} coupling constants support a conformation in solution that is predominantly 2'-endo (*S*). Although conformationally and sterically nucleoside **3** may resemble other thymidine analogs which are active against HIV-1, **3** is virtually inactive.

One of the most active nucleoside analogs against HIV-1 is 3'-fluoro-3'-deoxythymidine (**1**).^{3,4} This nucleoside is a more potent inhibitor of HIV-1 replication in vitro than 3'-azidothymidine (**2**) (Table I). We previously reported that the analog with an additional 3'-fluoro substituent, 3',3'-difluoro-3'-deoxythymidine (**3**), is virtually inactive against HIV-1.⁵ On the basis of calculations using MINDO/3, a semiempirical, all-valence-electron molecular

orbital method, we postulated that the 3'-fluoro, located on the same face of the furanose as the thymine, strongly influenced the conformation about the glycosidic bond and led to a substantial preference for the N (3'-endo, 2'-exo) conformation of the deoxyribose. On the basis of NMR experiments reported here, that prediction is not born out.

The synthesis of 3',3'-difluoro-3'-deoxythymidine is outlined in Figure 1. Although the synthesis was previously reported, the experimental details, the structure determination, and the data on antiviral activity have not been published previously.^{6,7} The first two steps, tritylation of thymidine and the oxidation of 5'-O-tritylthymidine to yield 3'-ketothymidine (**5**) have been previously described in detail.⁸ Fluorination was accom-

(1) (a) Purdue University. (b) Rega Institute for Medical Research.

(2) Present address: 3M Research Limited, Pinnacles, Harlow, Essex, England CM19 5AE.

(3) Herdewijn, P. A. M.; Van Aerschot, A.; Balzarini, J.; De Clercq, E.; Everaert, D. H.; De Winter, H. L.; Peeters, O. M.; Blaton, N. M.; De Ranter, C. J. 3'-Fluoro- and 3'-azido-substituted 2',3'-dideoxynucleosides: Structure-activity relationship. *Med. Chem. Res.* 1991, 1, 9–19.

(4) Etzold, G.; Hintsche, R.; Kowollik, G.; Langen, P. Nucleoside von fluorzuchen. VI. Synthese und reaktivitat von 3'-fluor- und 3'-chlor-3'-deoxy-thymidin. *Tetrahedron* 1971, 27, 2463–2472.

(5) Bergstrom, D. E.; Swartling, D. J.; Wisor, A.; Hoffmann, M. R. Evaluation of thymidine, dideoxythymidine and fluorine substituted deoxyribonucleoside geometry by the MINDO/3 technique: The effect of fluorine substitution on nucleoside geometry and biological activity. *Nucleosides Nucleotides* 1991, 10, 693–697.

(6) Bergstrom, D. E.; Romo, E. H.; Mott, A. W. Synthesis of gem-difluoro substituted nucleoside analogs. *Book of Abstracts*, 185th ACS National Meeting, Seattle, WA, March 20–25, 1983; American Chemical Society: Washington, DC, 1983; CARB 38.

(7) Jarvi, E. T.; Sunkara, P. S.; Bowlin, T. L. Synthesis and biological evaluation of dideoxynucleosides containing a difluoromethylene unit. *Nucleosides Nucleotides* 1989, 8, 1111–1114.

(8) Froehlich, M. L.; Swartling, D. J.; Lind, R. E.; Mott, A. W.; Bergstrom, D. E. An improved synthesis of 3'-keto-5'-O-trityl-thymidine. *Nucleosides Nucleotides* 1989, 8, 1529–1535.